Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels

European Journal of Cancer

Volumn 44, Issue 6, 2008, Pages 898-906

  Verschoyle, Richard D ^a   Greaves, Peter ^a   Patel, Ketan ^a   Marsden, Debbie A ^a   Brown, Karen ^a   Steward, William P ^a   Gescher, Andreas J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Chemoprevention; IGF; Preclinical models; Silibinin

Indexed keywords

APC PROTEIN; PHOSPHOLIPID; SILIBININ; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENETIC MODEL; INTESTINE CARCINOGENESIS; INTESTINE CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEANING;

ADENOMA; ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; PHOSPHATIDYLCHOLINES; PROSTATIC NEOPLASMS; SILYMARIN;

EID: 41949087545     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.02.020     Document Type: Article

References (44)

1. Singh R.P., Dhanalakshmi S., Tyagi A.K., et al. Dietary feeding of silibinin inhibits advanced human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 62 (2002) 3063-3069
2. Kohno H., Suzuki R., Sugie S., et al. Dietary supplementation with silymarin inhibits 3,2′-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats. Clin Cancer Res 11 (2005) 6492-6497
3. Katiyar S.K., Korman N.J., Mukhtar H., and Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 89 (1997) 556-566
4. Lahiri-Chatterjee M., Katiyar S.K., Mohan R.R., and Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 59 (1999) 622-632
5. Vinh P.Q., Sugie S., Tanaka T., et al. Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Jap J Cancer Res 93 (2002) 42-49
6. Gershbein L.L. Action of dietary trypsin, pressed coffee, silymarin and iron salt on 1,2-dimethylhydrazine tumorigenesis by gavage. Anticancer Res 14 (1994) 1113-1116
7. Kohno H., Tanaka T., Kawabata K., et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 101 (2002) 461-468
8. Volate S.R., Davenport D.M., Muga S.J., and Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 26 (2005) 1450-1456
9. Comoglio A., Leonarduzzzi G., Carini R., et al. Studies on the antioxidant and free radical scavenging properties of IdB 1016: a new flavonolignan complex. Free Radic Res Commun 11 (1990) 109-115
10. Hoh C., Boocock D., Marczylo T., et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: assessment of silibinin levels in plasma, colorectum and liver and their pharmacodynamic consequences. Clin Cancer Res 12 (2006) 2944-2950
11. Barzaghi N., Crema F., Gatti G., et al. Pharmacokinetic studies on IdB 1016, a sylibin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokin 15 (1990) 333-338
12. Greenberg N.M., DeMayo F., Finegold M.J., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92 (1995) 3439-3443
13. Gingrich J.R., Barrios R.J., Foster B.A., and Greenberg N.M. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prost Cancer Prost Dis 2 (1999) 70-75
14. Luongo C., Moser A.R., Gledhill S., and Dove W.F. Loss of Apc(+) in intestinal adenomas from Min mice. Cancer Res 54 (1994) 5947-5952
15. Mentor-Marcel R., Lamartiniere C.A., Eltoum I.E., et al. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61 (2001) 6777-6782
16. Gupta S., Hastak K., Ahmand N., et al. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98 (2001) 10350-10355
17. Mahmoud N.N., Carothers A.M., Grunberger D., et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21 (2000) 921-927
18. Perkins S., Verschoyle R.D., Hill K., et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11 (2002) 535-540
19. Ahmad N., Gali H., Javed S., and Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation of cell cycle progression. Biochem Biophys Res Commun 247 (1998) 294-301
20. Zi X., Grasso A.W., Kung H.J., and Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58 (1998) 1920-1929
21. Zi X., and Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 96 (1999) 7490-7495
22. Jiang C., Agarwal R., and Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem Biophys Res Commun 276 (2000) 371-378
23. Butt A.J., Firth S.M., and Baxter R.C. The IGF axis and programmed cell death. Immunol Cell Biol 77 (1999) 256-262
24. Lopez T., and Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in mouse model of pancreatic islet tumorigenesis. Cancer Cell 1 (2002) 339-353
25. Samani A.A., Chevet E., Fallavollita L., et al. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 64 (2004) 3380-3385
26. Chan J.M., Stampfer M.J., Ma J., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94 (2002) 1099-1106
27. Allen N.E., Key T.J., Appleby P.N., et al. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 16 (2007) 1121-1127
28. Zi X., Zhang J., Agarwal R., and Pollak M. Silibinin up-regulates insulin-like growth factor binding protein-3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60 (2000) 5617-5620
29. Flaig T.W., Gustafson D.L., Su L.J., et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigat New Drugs 25 (2007) 139-146
30. Workman P., Twentyman P., Balkwill F., et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77 (1998) 1-10
31. Freireich E.J., Gehan E.A., Rall D.P., et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50 (1966) 219-244
32. Strumia M.M., Sample A.B., and Hart E.D. An improved micro hematocrit method. Am J Clin Pathol 24 (1954) 1016-1024
33. Shappell S.B., Thomas G.V., Roberts R.L., et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 64 (2004) 2270-2305
34. Shukla S., Mishra A., Fu P., et al. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J 19 (2005) 2042-2044
35. Lee H.L., Chang Y.S., Han J.Y., et al. Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. J Natl Cancer Inst 23 (2005) 4439-4449
36. Hoh C.S.L., Boocock D.J., Marczylo T.H., et al. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high performance liquid chromatography, and identification of possible metabolites. J Agric Food Chem 55 (2007) 2532-2535
37. Raina K., Blouin M.J., Singh R.P., et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67 (2007) 11083-11091
38. Kaplan P.J., Mohan S., Cohen P., et al. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59 (1999) 2203-2209
39. Grzmil M., Hemmerlein B., Thelen P., et al. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, upregulates IGF binding protein-3 and suppresses MMP-2 expression. J Pathol 202 (2004) 50-59
40. Stattin P., Kaaks R., Riboli E., et al. Circulating insulin-like growth factor-I and benign prostatic hyperplasia. A prospective study. Scand J Urol Nephrol 35 (2001) 122-126
41. Zhang D., Samani A.A., and Brodt P. The role of the IGF-1 receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis. Horm Metab Res 35 (2003) 802-808
42. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
43. Oh Y., Gucev Z., Ng L., et al. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP-3) in human breast cancer cells. Prog Growth Factor Res 6 (1995) 503-512
44. Valentinis B., Bhala A., DeAngelis T., et al. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-1 receptor gene. Mol Endocrinol 9 (1995) 361-367